[go: up one dir, main page]

MX2021001654A - Lipido cationico. - Google Patents

Lipido cationico.

Info

Publication number
MX2021001654A
MX2021001654A MX2021001654A MX2021001654A MX2021001654A MX 2021001654 A MX2021001654 A MX 2021001654A MX 2021001654 A MX2021001654 A MX 2021001654A MX 2021001654 A MX2021001654 A MX 2021001654A MX 2021001654 A MX2021001654 A MX 2021001654A
Authority
MX
Mexico
Prior art keywords
sub
straight
chain
alkyl group
cationic lipid
Prior art date
Application number
MX2021001654A
Other languages
English (en)
Inventor
Yasuhiro Sawai
Yasutaka Hoashi
Satoru Matsumoto
Yoshimasa Omori
Masahiro Mineno
Nozomu KAKIMOTO
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2021001654A publication Critical patent/MX2021001654A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/06—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención proporciona una técnica capaz de transferir un ingrediente activo, particularmente, un ácido nucleico a una célula con excelente eficacia y un lípido catiónico para usarse en esta técnica, etc. El lípido catiónico de la presente invención es un compuesto representado por la fórmula (I) o una sal del mismo. n1 representa un número entero de 2 a 6, n2 representa un número entero de 0 a 2, n3 representa un número entero de 0 a 2, L representa -C(O)O- o -NHC(O)O-, Ra representa un grupo alquilo de C5-13 lineal, un grupo alquenilo de C13-17 lineal o un grupo alcadienilo de C17 lineal, Rb representa un grupo alquilo de C2-9 lineal, Rc representa un átomo de hidrógeno o un grupo alquilo de C2-9 lineal, Rd representa un átomo de hidrógeno o un grupo alquilo de C2-9 lineal, Re representa un grupo alquilo de C2-9 lineal, y Rf representa un grupo alquilo de C2-9 lineal. (ver Fórmula).
MX2021001654A 2018-08-10 2019-08-08 Lipido cationico. MX2021001654A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018151583 2018-08-10
PCT/JP2019/031411 WO2020032184A1 (ja) 2018-08-10 2019-08-08 カチオン性脂質

Publications (1)

Publication Number Publication Date
MX2021001654A true MX2021001654A (es) 2021-05-12

Family

ID=69414814

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001654A MX2021001654A (es) 2018-08-10 2019-08-08 Lipido cationico.

Country Status (19)

Country Link
US (1) US12479791B2 (es)
EP (1) EP3835287B1 (es)
JP (1) JP7350749B2 (es)
KR (1) KR102689017B1 (es)
CN (2) CN117304048A (es)
AU (1) AU2019317095B2 (es)
BR (1) BR112021002384B1 (es)
CA (1) CA3109207A1 (es)
CO (1) CO2021001745A2 (es)
DK (1) DK3835287T3 (es)
ES (1) ES3001457T3 (es)
FI (1) FI3835287T3 (es)
IL (1) IL280620B2 (es)
MX (1) MX2021001654A (es)
PL (1) PL3835287T3 (es)
PT (1) PT3835287T (es)
SG (1) SG11202101356YA (es)
TW (1) TWI837161B (es)
WO (1) WO2020032184A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI837161B (zh) 2018-08-10 2024-04-01 日商武田藥品工業股份有限公司 陽離子性脂質
CN115989511A (zh) 2020-08-31 2023-04-18 武田药品工业株式会社 推理装置、推理方法、推理程序、模型生成方法、推理服务提供系统、推理服务提供方法以及推理服务提供程序
MX2023003345A (es) * 2020-09-23 2023-07-24 Translate Bio Inc Lípidos catiónicos basados en tes.
CA3237659A1 (en) 2021-11-10 2023-05-19 Takeda Pharmaceutical Company Limited Cationic lipid
EP4489009A1 (en) 2022-02-28 2025-01-08 Takeda Pharmaceutical Company Limited Inference device, generation device, inference program, and generation program
CN119998259A (zh) * 2022-06-23 2025-05-13 特恩生物技术公司 脂质结构及包含其的组合物
WO2024026308A2 (en) 2022-07-29 2024-02-01 Massachusetts Institute Of Technology COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE SIGNAL REGULATORY PROTEIN ALPHA (SIRPα) GENE
EP4630561A1 (en) 2022-12-09 2025-10-15 Takeda Pharmaceutical Company Limited Modified immunomodulators
EP4635939A1 (en) * 2022-12-12 2025-10-22 Korea Institute of Science and Technology Novel lipid compound and lipid nanoparticle composition comprising same
WO2024140546A1 (zh) * 2022-12-26 2024-07-04 北京新合睿恩生物医疗科技有限公司 一种阳离子脂质化合物及制备方法和应用、mRNA递送系统
TW202449142A (zh) 2023-04-07 2024-12-16 日商武田藥品工業股份有限公司 接合複合物
WO2024236361A1 (en) 2023-05-15 2024-11-21 Takeda Pharmaceutical Company Limited Compositions and methods for delivery of nucleic acids to cells
WO2024236504A1 (en) 2023-05-15 2024-11-21 Takeda Pharmaceutical Company Limited Sequences and methods for delivery of dna and rna
WO2024249525A1 (en) * 2023-05-30 2024-12-05 Liberate Bio, Inc. Lipid compounds, compositions, and uses thereof
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
DE4418965A1 (de) 1994-05-31 1995-12-07 Boehringer Ingelheim Int Verfahren zum Einbringen von Nukleinsäure in höhere eukaryotische Zellen
US5981501A (en) * 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US6235310B1 (en) 1997-04-04 2001-05-22 Valentis, Inc. Methods of delivery using cationic lipids and helper lipids
US7223887B2 (en) 2001-12-18 2007-05-29 The University Of British Columbia Multivalent cationic lipids and methods of using same in the production of lipid particles
US20040043952A1 (en) 2002-05-31 2004-03-04 Genteric, Inc. Multifunctional polyamines for delivery of biologically-active polynucleotides
EP2338478B1 (en) * 2002-06-28 2014-07-23 Protiva Biotherapeutics Inc. Method for producing liposomes
EP1766035B1 (en) 2004-06-07 2011-12-07 Protiva Biotherapeutics Inc. Lipid encapsulated interfering rna
KR101529317B1 (ko) 2005-06-22 2015-06-16 아스테리아스 바이오세라퓨틱스, 인크. 영장류 다능성 줄기 세포의 심근세포 계통 세포로의 분화
US20080145413A1 (en) 2006-12-19 2008-06-19 Steffen Panzner Lipids and lipid assemblies comprising transfection enhancer elements
KR100807060B1 (ko) 2007-08-28 2008-02-25 고려대학교 산학협력단 신규한 양이온성 지질, 그의 제조 방법 및 그를 포함하는전달체
WO2009046220A2 (en) 2007-10-02 2009-04-09 Mdrna, Inc. Lipopeptides for delivery of nucleic acids
JP5611035B2 (ja) 2008-03-26 2014-10-22 国立大学法人京都大学 胚性幹細胞および人工多能性幹細胞由来からの高心臓形成性前駆細胞および心筋細胞の効率的製造および使用
JP2010158206A (ja) 2009-01-08 2010-07-22 National Institute Of Advanced Industrial Science & Technology ヒト心筋前駆細胞の選別方法
KR101198715B1 (ko) * 2010-05-14 2012-11-13 한국생명공학연구원 핵산 및 친수성 음이온 화합물의 고효율 포획을 위한 비대칭 리포솜 및 이의 제조방법
KR101187064B1 (ko) 2010-07-18 2012-09-28 주식회사 바이오폴리메드 양이온성 지질, 이의 제조 방법 및 이를 포함하는 세포내 이행성을 갖는 전달체
EP3460064B8 (en) 2011-04-03 2024-03-20 The General Hospital Corporation d/b/a Massachusetts General Hospital Efficient protein expression in vivo using modified rna (mod-rna)
JP6305343B2 (ja) * 2011-12-07 2018-04-04 アルニラム・ファーマシューティカルズ・インコーポレーテッド 活性薬剤の送達のための分岐アルキルおよびシクロアルキルを末端とする生分解性脂質
RS58077B1 (sr) 2012-02-24 2019-02-28 Arbutus Biopharma Corp Trialkil katjonski lipidi i postupci njihove primene
TW201726600A (zh) 2012-07-06 2017-08-01 協和醱酵麒麟有限公司 陽離子性脂質
WO2014071072A2 (en) 2012-11-02 2014-05-08 Pungente Michael D Novel cationic carotenoid-based lipids for cellular nucleic acid uptake
CN105873902B (zh) 2013-11-18 2019-03-08 阿克丘勒斯治疗公司 用于rna递送的可电离的阳离子脂质
PL3083556T3 (pl) * 2013-12-19 2020-06-29 Novartis Ag Lipidy i kompozycje lipidowe dla dostarczania środków czynnych
WO2015141827A1 (ja) 2014-03-20 2015-09-24 国立大学法人京都大学 心筋細胞の選別方法
SG11201700828PA (en) * 2014-08-07 2017-03-30 Takeda Pharmaceuticals Co Cationic lipid
WO2016121942A1 (ja) 2015-01-30 2016-08-04 日油株式会社 カチオン性脂質
JP6719352B2 (ja) 2016-09-23 2020-07-08 株式会社総合車両製作所 車両用内装パネルとその製造方法
WO2018062413A1 (ja) * 2016-09-28 2018-04-05 協和発酵キリン株式会社 核酸含有脂質ナノ粒子
CA3045122A1 (en) 2016-12-09 2018-06-14 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
US20210052646A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Nucleic-acid containing lipid nano-particle and use thereof
MX2020006800A (es) 2017-12-28 2020-09-03 Takeda Pharmaceuticals Co Lipidos cationicos.
CN111527204B (zh) 2017-12-28 2023-09-01 国立大学法人京都大学 靶基因改造用组合物
TWI837161B (zh) 2018-08-10 2024-04-01 日商武田藥品工業股份有限公司 陽離子性脂質
CN116969851A (zh) 2022-04-29 2023-10-31 北京剂泰医药科技有限公司 可电离脂质化合物
CN115850104B (zh) 2022-04-29 2023-07-18 北京剂泰医药科技有限公司 可电离脂质化合物

Also Published As

Publication number Publication date
PT3835287T (pt) 2024-12-05
SG11202101356YA (en) 2021-03-30
JP7350749B2 (ja) 2023-09-26
BR112021002384B1 (pt) 2024-01-23
TWI837161B (zh) 2024-04-01
CN112533893A (zh) 2021-03-19
CA3109207A1 (en) 2020-02-13
PL3835287T3 (pl) 2025-01-20
DK3835287T3 (da) 2025-01-02
CN112533893B (zh) 2023-12-22
JPWO2020032184A1 (ja) 2021-08-26
TW202021945A (zh) 2020-06-16
US12479791B2 (en) 2025-11-25
AU2019317095B2 (en) 2024-05-02
ES3001457T3 (en) 2025-03-05
US20220098142A1 (en) 2022-03-31
BR112021002384A2 (pt) 2021-05-11
EP3835287B1 (en) 2024-10-02
IL280620B1 (en) 2024-02-01
WO2020032184A1 (ja) 2020-02-13
CN117304048A (zh) 2023-12-29
FI3835287T3 (fi) 2024-12-03
AU2019317095A1 (en) 2021-03-11
IL280620B2 (en) 2024-06-01
CO2021001745A2 (es) 2021-03-08
KR20210042089A (ko) 2021-04-16
KR102689017B1 (ko) 2024-07-26
EP3835287A1 (en) 2021-06-16
EP3835287A4 (en) 2022-06-08
IL280620A (en) 2021-03-25

Similar Documents

Publication Publication Date Title
MX2021001654A (es) Lipido cationico.
MX2020006800A (es) Lipidos cationicos.
EA200601620A1 (ru) 5,6-диалкил-7-аминотриазолопиримидины, способ их получения и их применение для борьбы с патогенными растениями, а также содержащие их средства
GEP201706728B (en) Noxious organism control agent
PH12021551878A1 (en) Nucleic acid release agent, nucleic acid pcr amplification method and pcr amplification kit
MX2023015423A (es) Ligando de acido nucleico y conjugado, metodo de preparacion y uso del mismo.
MX392756B (es) Pirimidinas modificadas en la posicion 5 y su uso
EA201590035A1 (ru) Способ получения кондиционирующей композиции для волос
TN2012000543A1 (en) Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
UA95976C2 (en) 2-ARYL-6-PHENYLIMIDAZO[1,2-b]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
TW200731013A (en) Salt suitable for an acid generator and a chemically amplified resist composition containing the same
EP3388426A3 (en) Compounds for protection of cells
MX369016B (es) Método de extracción de ácido desoxirribonucleico/ácido ribonucleico usando compuestos de amonio cuaternario sililados.
BR112013021941A2 (pt) agente terapêutico para tumor
RU2016117113A (ru) Микробицидная композиция, содержащая бензоат или сорбат
PE20080949A1 (es) Azolilmetiloxiranos, su uso para combatir hongos fitopatogenos, asi como productos que los contienen
GB0401336D0 (en) Organic compounds
EP3444887A3 (en) Disulfonate-based additive and lithium secondary battery comprising the same
CL2019000017A1 (es) Procesos novedosos para la preparación de estimuladores de guanilato ciclasa soluble.
MY165143A (en) Detergent and liquid detergent for textile products
MX2017007385A (es) Estabilizacion de nanoparticulas hexagonales de nitruro de boro.
WO2013153054A3 (en) Process for the preparation of polyoxyalkylene aminophosphonic dispersing agents
MX342390B (es) Proceso para preparar 3-haloalquilpirazoles.
RU2017108571A (ru) Ингибитор биологической коррозии металлов
CY1116477T1 (el) Μεθοδος εnzυμatiκης συνθεσης toy (7s)-3,4-διμεθοξυδικυκλο[4.2.0] οκτα-1,3,5-τριενo-7-καρβοξυλικου οξεος ή εστερων αυτου και εφαρμογη στην συνθεση της ιβαμπραδινης και των αλατων αυτης